Drugs / GP40221
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06497049 | Jun 2023 → May 2024 | — | Geropharm | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GP40221 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06497049 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06497049 ↗ |